CytomX Therapeutics (CTMX) Profit After Tax (2016 - 2025)
Historic Profit After Tax for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' Profit After Tax fell 34806.49% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10258.86%. This contributed to the annual value of $31.9 million for FY2024, which is 570087.87% up from last year.
- As of Q3 2025, CytomX Therapeutics' Profit After Tax stood at -$14.2 million, which was down 34806.49% from -$154000.0 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Profit After Tax ranged from a high of $23.5 million in Q1 2025 and a low of -$34.8 million during Q4 2021
- Its 5-year average for Profit After Tax is -$9.2 million, with a median of -$6.5 million in 2024.
- The largest annual percentage gain for CytomX Therapeutics' Profit After Tax in the last 5 years was 215519.71% (2024), contrasted with its biggest fall of 50110.4% (2024).
- Over the past 5 years, CytomX Therapeutics' Profit After Tax (Quarter) stood at -$34.8 million in 2021, then soared by 74.8% to -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then surged by 2155.2% to $18.9 million in 2024, then crashed by 175.38% to -$14.2 million in 2025.
- Its last three reported values are -$14.2 million in Q3 2025, -$154000.0 for Q2 2025, and $23.5 million during Q1 2025.